Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944889 | 0.98 | PDK2 (0.43) | PDK2PARP10PARP15RBP4 | |
| SCHEMBL22816889 | 0.94 | RBP4 (0.41) | PDK2PARP10PARP15RBP4CHRNB4 | |
| SCHEMBL21944812 | 0.85 | NFE2L2 (0.47) | — | |
| SCHEMBL21945551 | 0.81 | IDO1 (0.41) | PDK2RBP4 | |
| SCHEMBL18002262 | 0.79 | KDM1A (0.44) | PDK2PARP10PARP15 | |
| SCHEMBL18002270 | 0.78 | KDM1A (0.43) | PDK2PARP10PARP15 | |
| SCHEMBL18002433 | 0.78 | TLR4 (0.41) | PDK2PARP10PARP15RBP4 | |
| SCHEMBL18002090 | 0.77 | TLR4 (0.43) | PDK2PARP10PARP15RBP4 | |
| SCHEMBL18002261 | 0.77 | TLR4 (0.43) | PDK2PARP10PARP15RBP4 | |
| SCHEMBL17534303 | 0.76 | CNR1 (0.46) | PARP10PARP15CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | PDK2 123/4885PARP10 3605/4885PARP15 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.